p.Y420C) in the proband. NRAP is a multi-domain scaffolding protein involved in cardiac muscle thin filament assembly, myofibril and actin cytoskeleton organization. The respective NRAP (p.Y420C) is predicted to be pathological by in -silico analysis and might be potentially influencing its functions. Targeted re-sequencing in an independent cohort resulted in identification of the same amino acid change in an unrelated eighty-six years old patient. The protein-protein interactions (PPI) network analysis revealed NRAP is strongly associated with other known elderly and late-onset HCM genes/proteins. In line with these data, both the study patients are late-onset in nature. Our study for the first time reveals the association of NRAP in the elderly and late-onset HCM patients and further expands the genotypic-phenotypic spectrum of HCM.
INTRODUCTION:
HCM is a disease of heart muscles, which is characterized by abnormally muscle thickening finally leading to systolic dysfunction (1, 2) . More often, mutations in several sarcomere genes are primary cause of familial and non-familial HCM. Clinical expression of HCM starts generally in the early age (~20 years of age) and progress quickly in middle age of the patients (~40 years of age). In contrast, in the elderly patients the symptoms remain silent but develop after an average age of 66 years (3) . Till date, little is known about the elderly and late-onset HCM genes and only a few sarcomeric genes such as Myosin binding protein C3 (MYBPC3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI1 and TNNI3), myosin light chain 3 (MYL3), alpha-cardiac myosin heavy chain 6 (MYH6) and beta-cardiac myosin heavy chain 7 (MYH7) are shown to be associated with elderly and late-onset HCM (4-9). Here, we analyzed a clinically well characterized Indian family with a history of late-onset HCM and performed whole-exome sequencing (WES) and analysis. We identified a novel missense variant in NRAP (NM_001261463, c.1259A>G, p.Y420C) in the proband compared to the healthy familial controls. Targeted re-sequencing in an independent cohort resulted in identification of a separate elderly patient with the same gene variant. Computational analysis using PPI and pathway analysis also suggest strong association of NRAP with known elderly and late-onset HCM genes.
MATERIALS AND METHODS:

Study participants:
Blood samples from study participants and their clinical reports were obtained from Government Medical College, Kozhikode and Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, India. We analyzed five subjects from a single HCM family with informed consents. Echocardiograms (Echo) were performed on all the study participants. The study was conducted in accordance with the 'Declaration of Helsinki' and was approved by the respective hospitals and Institutional ethics committees. Genomic DNA was extracted from peripheral blood samples using standard procedures (phenol-chloroform method) for molecular analysis (5) .
Genetic analysis:
To identify potential causal genetic variant in the patient, whole exome sequencing (WES) was performed for a proband (2II) who is negative for sarcomeric gene mutations and an unaffected available healthy family member (2IV) ( Figure 1A) . Sequencing was performed using the respective service providers including institutional sequencing facility after de-identifying the patient details. For each exome paired end 100 base pair reads (100X coverage) was employed and 6 Gb data was obtained. Exome analysis and variant calling were performed using in-house custom pipeline as outlined in the Figure 1B . Low quality reads were filtered and adapters were removed using Trimmomatic. Exomes were first mapped on to the human reference genome (GRCh38) using Burrows-Wheeler aligner (BWA-MEM 
Protein-protein interaction (PPI) analysis:
HCM-associated genes were extracted (10) and protein-protein interaction network was constructed with identified potential gene (NRAP) from patient's exome data. PPI network using STRING database (based on protein coexpression, experimentally determined interaction and various database annotation) and pathway analysis were performed using ClugoVs from Cytoscape 3.6.0 (www.cytoscape.org/). Only significant pathways with ≤ 0.005 were considered for pathway enrichment. Conservation alignment was performed using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/).
RESULTS
Exome sequencing and analysis:
The WES resulted in an average of 702.65 million clean reads in 2 subjects (2II and 2IV). We obtained 75.6 thousand single nucleotide polymorphisms (SNPs) and 9.1 thousand insertion/deletion/frameshift variants (InDels) in the proband, and 79.9
thousand SNPs and 9.2 thousand InDels in the healthy family member. By using the variant calling and filtering pipeline outlined in the methods section, we identified a missense heterozygous mutation in the NRAP as a potential candidate in the proband (Figure 1B) . The Figure 1D) . The variant was absent in 320 population stratified South Indian healthy individuals from the same ethnicity and geographical region. The baseline details of the control subjects are described previously by us (5) . It was also absent in the 94 healthy ageing Indians above 80 years old without any medical conditions (www.idhans.org).
Genotype-phenotype correlations: Patient (2II) was diagnosed with HCM at the age of 61 with LVIDD and LVIDS being 44 mm and 24 mm respectively, LVEF was 68% and IVS was 22 mm.
For an unrelated HCM patient in the replication cohort, the age of onset was 70 years with the respective echo parameters: LVIDD: 43 mm, LVIDS: 29 mm, LVEF: 60% and IVS: 21 mm.
PPI network analysis:
We performed PPI network analysis between NRAP and known HCM-associated genes to understand the potential molecular connection of NRAP with HCM. Network analysis revealed NRAP is strongly connected with HCM-associated genes including six known elderly and lateonset HCM genes as highlighted in the Figure 2A. In addition, the pathway enrichment analysis also showed a significant link between NRAP and HCM pathways including sarcomere organization, cardiac muscle cell development, cardiac myofibril assembly, striated muscle myosin thick filament, muscle alpha-actinin binding and cellular homeostasis (Figure 2A) .
Notably, the Y420 residue is located in the simple repeat domain of the NRAP (Figure 2B) , which is known to interact with HCM-associated proteins α -actinin, actin, muscle LIM protein (MLP) and Kelch-like family member 41 (KLHL41).
DISCUSSION:
Here, we provide first evidence that a NRAP missense mutation is associated with elderly and late-onset HCM. NRAP is crucial for cardiac muscle thin filament assembly, actin cytoskeleton organization, and myofibril assembly in cardiomyocytes. NRAP is a multidomain scaffolding Cardiomyopathy (DCM) (16) . Furthermore, compound heterozygous missense mutations leading to amino acid changes at the position 282 from alanine to threonine, 519 from asparagine to isoleucine and 1225 from alanine to valine have been found in a single patient of myofibril myopathy (MFM) (17) . A recent study has shown the pathologically increased levels of NRAP contributing to muscle dysfunction in Nemaline myopathy (NM) by interacting KLHL41. Of note, NM has been shown to have strong association with HCM (18, 19) . In addition, overexpression of NRAP is found to be associated with ventricular hypertrophy and dysfunction in a mouse model (20) . Thus, loss of function NRAP mutations are associated with DCM whereas overexpression (or) gain of function leads to cardiac hypertrophy. So far, all the NRAP variants reported (Figure 2C) are loss-of-function mutations with respective to early-onset diseases. In contrast, our study for the first time suggests a missense amino acid change in the NRAP at 420 th residue leading to elderly and late-onset HCM. We presume, further analysis of NRAP mutations in the larger cohorts, will establish the causal link for NRAP in the HCM. 
